VKH
OREX

Virtu KCG Holdings’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Virtu KCG Holdings’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-1,120
Closed -$68K – 4531
2014
Q4 		$68K Buy
+1,120
New +$56.3K ﹤0.01% 3355

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OWIM
Old West Investment Management Los Angeles, California $923M AUM 112.31% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Virtu KCG Holdings's OREX Position: Q2 2017 in Review

Virtu KCG Holdings reduced its Orexigen Therapeutics, Inc. (OREX) stake by 68% in Q2 2017, selling an estimated $89.1K and leaving 14,238 shares worth $41K. The position accounts for ﹤0.01% of the portfolio, ranked #2636.

Virtu KCG Holdings first reported a position in OREX in Q3 2013 and has held it in 15 quarters since. The position peaked at $405K in Q1 2014. 51 funds tracked by Wall St. Rank hold OREX as of Q2 2017.

  • Virtu KCG Holdings held 14,238 shares of Orexigen Therapeutics, Inc. worth $41K as of Q2 2017.
  • Virtu KCG Holdings sold 29,716 Orexigen Therapeutics, Inc. shares in Q2 2017, an estimated $89.1K.
  • Orexigen Therapeutics, Inc. made up ﹤0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #2636 holding.
  • Virtu KCG Holdings first reported a position in Orexigen Therapeutics, Inc. in Q3 2013 and has held it in 15 quarters since.
  • Virtu KCG Holdings's Orexigen Therapeutics, Inc. position peaked at $405K in Q1 2014.
  • 51 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.